FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2973171639> ?p ?o ?g. }

• W2973171639 endingPage "S140" @default.
• W2973171639 startingPage "S139" @default.
• W2973171639 abstract "The role of adjuvant WBRT in MBMs is controversial. This phase 3 trial compares WBRT with Obs following local treatment of 1-3 MBMs. The primary endpoint is distant intracranial failure (DIF) within 12 months of randomization. The a priori neurocognitive function (NCF) endpoint is Hopkins Verbal Learning Test-Revised (HVLT-R) delayed recall at 4 months. Secondary endpoints include local failure (LF), overall survival (OS) and global quality of life (QoL). Analyses were conducted on intention-to-treat basis with nominal two-sided significance level 5%. Drug therapy was allowed. Effective drugs became available during the trial and their impact was analyzed. Of 586 eligible patients, 215 consented from 31 sites in 3 countries (Australia, UK and Norway) between 2009 and 2017. Eight (0.04%) who withdrew or had no data collected were excluded. 107 were randomized to Obs and 100 to WBRT. Mean age was 62 years, 67% were males, 61% with single MBM of mean size 2cm, 67% had extracranial disease at randomization. The two arms were well matched. NCF was completed by English speakers; 50 WBRT and 70 Obs pts at baseline, declining to 26 and 35 respectively at 4 months. Within 12 months, 54 (50.5%) Obs patients had DIF compared with 42 (42.0%) WBRT patients (OR 0.71; 95% CI 0.41-1.23; p=0.222). There was no difference in LF (p=0.100) or OS (log-rank p=0.861). 53% (Obs) and 59% (WBRT) patients were alive at 12 months. There was no significant between-group difference in mean intervention effect on global QoL (p=0.083). Patients who received T-cell checkpoint inhibitors and/or mitogen-activated protein kinases (MAPK) pathway inhibitors and WBRT before or within 12 months of randomization had DIF rate 29% compared with Obs and no systemic therapy had 44%, but this was not significant (p=0.228). Obs patients had greater relative improvement from baseline in HVLT-R at every timepoint. At 4 months, Obs had 20.9% improvement from baseline in HVLT-R-delayed recall compared to 2.7% decline in WBRT; overall adjusted average intervention effect 23.6% (95%CI 9.0, 38.2; p = 0.0018). There was no difference in time to cognitive failure or in proportions with global cognitive impairment. This level one evidence shows WBRT does not improve outcomes in MBMs. This practice-changing trial justifies the recent move away from WBRT that occurred during the course of the trial." @default.
• W2973171639 created "2019-09-19" @default.
• W2973171639 creator A5000265791 @default.
• W2973171639 creator A5001979859 @default.
• W2973171639 creator A5015006267 @default.
• W2973171639 creator A5022076063 @default.
• W2973171639 creator A5022375432 @default.
• W2973171639 creator A5034265780 @default.
• W2973171639 creator A5034982958 @default.
• W2973171639 creator A5035263718 @default.
• W2973171639 creator A5040969461 @default.
• W2973171639 creator A5048478455 @default.
• W2973171639 creator A5051430596 @default.
• W2973171639 creator A5052434511 @default.
• W2973171639 creator A5052672458 @default.
• W2973171639 creator A5063202586 @default.
• W2973171639 creator A5076870664 @default.
• W2973171639 creator A5081735516 @default.
• W2973171639 creator A5085605664 @default.
• W2973171639 creator A5087304767 @default.
• W2973171639 creator A5088299044 @default.
• W2973171639 creator A5090390499 @default.
• W2973171639 date "2019-09-01" @default.
• W2973171639 modified "2023-09-28" @default.
• W2973171639 title "Phase 3 International Trial of Adjuvant Whole Brain Radiotherapy (WBRT) or Observation (OBS) Following Local Treatment of 1-3 Melanoma Brain Metastases (MBMs)" @default.
• W2973171639 doi "https://doi.org/10.1016/j.ijrobp.2019.06.133" @default.
• W2973171639 hasPublicationYear "2019" @default.
• W2973171639 type Work @default.
• W2973171639 sameAs 2973171639 @default.
• W2973171639 citedByCount "0" @default.
• W2973171639 crossrefType "journal-article" @default.
• W2973171639 hasAuthorship W2973171639A5000265791 @default.
• W2973171639 hasAuthorship W2973171639A5001979859 @default.
• W2973171639 hasAuthorship W2973171639A5015006267 @default.
• W2973171639 hasAuthorship W2973171639A5022076063 @default.
• W2973171639 hasAuthorship W2973171639A5022375432 @default.
• W2973171639 hasAuthorship W2973171639A5034265780 @default.
• W2973171639 hasAuthorship W2973171639A5034982958 @default.
• W2973171639 hasAuthorship W2973171639A5035263718 @default.
• W2973171639 hasAuthorship W2973171639A5040969461 @default.
• W2973171639 hasAuthorship W2973171639A5048478455 @default.
• W2973171639 hasAuthorship W2973171639A5051430596 @default.
• W2973171639 hasAuthorship W2973171639A5052434511 @default.
• W2973171639 hasAuthorship W2973171639A5052672458 @default.
• W2973171639 hasAuthorship W2973171639A5063202586 @default.
• W2973171639 hasAuthorship W2973171639A5076870664 @default.
• W2973171639 hasAuthorship W2973171639A5081735516 @default.
• W2973171639 hasAuthorship W2973171639A5085605664 @default.
• W2973171639 hasAuthorship W2973171639A5087304767 @default.
• W2973171639 hasAuthorship W2973171639A5088299044 @default.
• W2973171639 hasAuthorship W2973171639A5090390499 @default.
• W2973171639 hasBestOaLocation W29731716391 @default.
• W2973171639 hasConcept C118552586 @default.
• W2973171639 hasConcept C126322002 @default.
• W2973171639 hasConcept C141071460 @default.
• W2973171639 hasConcept C168563851 @default.
• W2973171639 hasConcept C169900460 @default.
• W2973171639 hasConcept C172467417 @default.
• W2973171639 hasConcept C203092338 @default.
• W2973171639 hasConcept C204243189 @default.
• W2973171639 hasConcept C509974204 @default.
• W2973171639 hasConcept C71924100 @default.
• W2973171639 hasConceptScore W2973171639C118552586 @default.
• W2973171639 hasConceptScore W2973171639C126322002 @default.
• W2973171639 hasConceptScore W2973171639C141071460 @default.
• W2973171639 hasConceptScore W2973171639C168563851 @default.
• W2973171639 hasConceptScore W2973171639C169900460 @default.
• W2973171639 hasConceptScore W2973171639C172467417 @default.
• W2973171639 hasConceptScore W2973171639C203092338 @default.
• W2973171639 hasConceptScore W2973171639C204243189 @default.
• W2973171639 hasConceptScore W2973171639C509974204 @default.
• W2973171639 hasConceptScore W2973171639C71924100 @default.
• W2973171639 hasIssue "1" @default.
• W2973171639 hasLocation W29731716391 @default.
• W2973171639 hasLocation W29731716392 @default.
• W2973171639 hasOpenAccess W2973171639 @default.
• W2973171639 hasPrimaryLocation W29731716391 @default.
• W2973171639 hasRelatedWork W1512088449 @default.
• W2973171639 hasRelatedWork W2113780394 @default.
• W2973171639 hasRelatedWork W2124688508 @default.
• W2973171639 hasRelatedWork W2414338203 @default.
• W2973171639 hasRelatedWork W2584850773 @default.
• W2973171639 hasRelatedWork W3129944423 @default.
• W2973171639 hasRelatedWork W3141563927 @default.
• W2973171639 hasRelatedWork W4244069386 @default.
• W2973171639 hasRelatedWork W4250883221 @default.
• W2973171639 hasRelatedWork W4306253774 @default.
• W2973171639 hasVolume "105" @default.
• W2973171639 isParatext "false" @default.
• W2973171639 isRetracted "false" @default.
• W2973171639 magId "2973171639" @default.
• W2973171639 workType "article" @default.